
ZTS AI Price Prediction
Track ZTS's AI-powered predictions, market trends, and investment insights.
You don't hold ZTS in your mock portfolio yet.
Track ZTS's AI-powered predictions, market trends, and investment insights.
You don't hold ZTS in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedBased on the provided valuation metrics, Zoetis appears to remain fundamentally profitable and reasonably valued despite the recent price decline. A PE ratio of 13.12 on EPS of 6.10 implies the market is pricing in moderate growth for a high‑quality, historically defensive animal‑health business. While we lack full income‑statement detail here, the combination of solid earnings power and a still‑profitable profile suggests the core business remains intact.
Zoetis’ stock has experienced a sharp drawdown, trading at $80.06 and down 31.5% in the last month, well below its 200‑day moving average of $128.05. This deep break below the long‑term trend line signals a strong downtrend and damaged sentiment, even if valuation has become more attractive. Without clear evidence of stabilization (e.g., basing pattern, improving momentum), the technical setup remains negative in the near term.
Alternative data for Zoetis show a mixed picture: digital engagement is stable to modestly growing, while hiring momentum has slowed meaningfully. Web traffic and app downloads are flat rather than expanding, which does not signal strong incremental demand, but also does not indicate a collapse in customer interest. Social media followings are inching higher, suggesting brand presence is intact, yet the 33% drop in job openings may reflect management caution or a shift toward efficiency over growth.
Zoetis appears fundamentally sound and profitable, with a valuation that has compressed to more attractive levels, but the stock’s technical profile is clearly negative after a severe recent drawdown. Alternative data are broadly stable with some cautionary signals from hiring, which does not offset the strong downside momentum in the share price. Overall, the setup leans bearish in the near term, with potential for a more constructive view if price action stabilizes and alternative indicators begin to re‑accelerate.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Zoetis (ZTS) is currently trading at $79.44 on the NYSE, representing a negligible single-day decline of 0.1%. With a market capitalization of $33.3 billion, ZTS remains one of the largest pure-play animal health companies globally, spanning livestock species such as cattle, swine, and poultry, as well as companion animals including dogs, cats, and horses. Daily volume of 5.29 million shares indicates steady institutional participation. The company's diversified commercial portfolio — spanning medicines, vaccines, and diagnostics — provides a degree of revenue resilience that analysts typically view as a structural advantage in the specialty pharma space.
TrendEdge's AI model currently assigns ZTS a score of 5 out of 10, reflecting a neutral outlook with no decisive bullish or bearish edge at this time. The score synthesizes available signals including price momentum, volume trends, and alternative data. Notably, app downloads have surged by an extraordinary 20,000%, suggesting a spike in consumer or investor engagement with Zoetis-related digital products. However, this single signal is not sufficient to elevate the overall score without corroborating momentum in price action or broader sentiment. With only 6 Reddit mentions tracked in the past seven days and no measurable sentiment skew, social conviction remains thin.
Looking ahead, key catalysts for ZTS include continued growth in its companion animal segment — historically the company's highest-margin business — and international expansion across emerging livestock markets. Risks include pricing pressure in generic animal health products, regulatory scrutiny on biologics approvals, and macroeconomic headwinds affecting livestock producer spending. The 129 active job postings signal moderate operational investment, but investors should monitor whether the unusual app download spike translates into measurable revenue or engagement metrics in upcoming earnings reports.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
291,548
Twitter Followers
16,197
Instagram Followers
62,102
YouTube Subscribers
6,700
LinkedIn Followers
626,371
Job Postings
129
LinkedIn Employees
13,488
News Mentions
1
Key Metrics